Ascend Montclair Pharmacy Launches Medical CBD SalesNote

Aug.22.2022
Ascend Montclair Pharmacy Launches Medical CBD SalesNote
Ascend Montclair pharmacy launched medical CBD last weekend, drawing in a steady crowd of customers.

Last Saturday, Ascend Montclair pharmacy launched medical CBD products during their weekend sale, attracting a steady stream of customers to the pharmacy.

 

Michele DeZao, a 60-year-old from Rockaway, was also among those who came to inspect. Two months ago, she obtained a medical CBD card and this was her second time visiting the pharmacy.

 

The cancer-disabled patient in recovery immediately noticed that the crowd on Saturday was increasing. However, she was relieved to have received priority treatment in the queue reserved only for medical patients to be discharged.

 

The hours between 8am to 10am are reserved exclusively for medical patients, while adult tobacco purchases begin at 10am every day of the week at Ascend Montclair.

 

I have no problem," Dezo said while paying, claiming it helps alleviate stomach pain. "Anyway, people are buying it (adult tobacco), so why not make it legal?

 

On August 20, 2022, Michele DeZao picked up her medical marijuana from Ascend Montclair pharmacy. The pharmacy, located at 395 Bloomfield Avenue, officially opened its doors on Friday at 10am and became the 19th pharmacy in New Jersey to sell adult-use cannabis after weeks of negotiations with the town. Alexandra Pais of NJ Advance Media captured the moment.

 

We appreciate the support of the Montclair community and are excited to share the Ascend experience with people in Montclair and surrounding towns," said Caitlin Fleishman, Public Affairs and Communications Director for Ascend Wellness, the multi-state operator of the pharmacy.

 

Last Tuesday, the Montclair Township administration voted 5-1 in favor of a pre-negotiated settlement agreement with Ascend, allowing for the sale of adult tobacco products.

 

Peter Yacobellis, the town consultant, stated that as part of the settlement agreement, Ascend Montclair will provide "voluntary donations" to various organizations using revenue from adult tobacco sales.

 

In an email, Yacobellis praised Ascend for their incredible generosity towards the citizens of Montclair, particularly their contributions to the Montclair Community Development Corporation and the Montclair Pre-K program. Yacobellis also emphasized the importance of ensuring that low-income and communities of color benefit from the revenue generated by the new cannabis market, as these communities have been disproportionately impacted by legacy marijuana laws.

 

The owner and co-founder of Ascend announced that another New Jersey location in Roselle Park launched adult tobacco sales statewide on April 21 and quickly became one of their top-performing adult cannabis stores in the U.S.

 

Ascend Fort Lee began selling medical marijuana on August 12th and plans to expand into adult CBD in the fall.

 

At Ascend Montclair, "there is a lot of traffic and support," said Fleishman.

 

Statement:

 

This article is compiled from third-party information and is intended solely for industry professionals for discussion and study purposes.

 

This article does not represent the views of 2FIRSTS, nor can 2FIRSTS confirm the truthfulness or accuracy of the article's content. The translation of this article is only intended for industry exchange and research.

 

Due to limitations in translation ability, this article may not accurately reflect the meaning of the original text. Please refer to the original text for accuracy.

 

2FIRSTS is in full agreement with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan or international issues and positions.

 

The compilation information is the property of the original media and author. If there is any infringement, please contact us for deletion.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
JTI Proposes 25-Cent Irish Cigarette Tax Increase, Says It Could Raise €45 Million
Japan Tobacco International's Irish business has proposed a €0.25 tax increase on a pack of 20 cigarettes in its pre-Budget 2027 submission, below the €0.50-or-more increases typically imposed in recent Irish budgets. JTI says the proposal could generate around €45 million in additional Exchequer revenue while limiting further movement toward illicit and non-Irish-tax-paid tobacco. Revenue's existing estimate for a comparable €0.25 increase, including pro-rata rises on other tobacco products, is about €18 million for a full year.
JTI
Sep.18 by 2Firsts Perspectives
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Latest UK ONS Data: Vaping Rate Edges Down to 9.9% in 2025, a Year After Overtaking Cigarette Smoking
Vaping prevalence in Great Britain edged down to 9.9% in 2025 from 10.0% in 2024, with the number of adult users holding at approximately 5.4 million for a second consecutive year, according to the Office for National Statistics (ONS). E-cigarette use had risen from 6.4% in 2020 to 10.0% in 2024, when it exceeded cigarette smoking prevalence for the first time. Cigarette smoking continued to decline to 8.7% in 2025, widening the gap to 1.2 percentage points. Daily vaping declined slightly, while usage among adults aged 25–34 increased despite falling rates in other age groups.
DATA
Oct.14
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
PMI's IQOS Extends ZAMNA Electronic-Music Partnership to Spain as Vogue España Publishes Branded Content
Philip Morris International's IQOS has extended its partnership with electronic-music event brand ZAMNA to Spain, setting up a House of IQOS at ZAMNA Madrid. Vogue España and Time Out Madrid subsequently published branded content clearly labeled as collaborations with IQOS. PMI has also expanded its company-owned IQOS boutique network in Spain to seven cities this year. The company says IQOS's adjusted heated-tobacco market share in Europe reached 12.6% in the first quarter of 2026, with Spain among its stronger-performing European markets.
Sep.20